In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $21.63 in the prior trading day, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $20.91, down -3.33%. In other words, the price has decreased by -$3.33 from its previous closing price. On the day, 1.62 million shares were traded. ARQT stock price reached its highest trading level at $21.84 during the session, while it also had its lowest trading level at $20.35.
Ratios:
Our goal is to gain a better understanding of ARQT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.04 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.79 whereas as Long-Term Debt/Eq ratio is at 0.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on July 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 02 ’25 when Edwards Larry Todd sold 4,504 shares for $20.04 per share. The transaction valued at 90,263 led to the insider holds 178,897 shares of the business.
Watanabe Todd sold 24,261 shares of ARQT for $469,074 on Oct 01 ’25. The insider now owns 867,179 shares after completing the transaction at $19.33 per share. On Oct 02 ’25, another insider, Watanabe Todd, who serves as the insider of the company, sold 20,739 shares for $20.04 each. As a result, the insider received 415,574 and left with 846,440 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 2507215104 and an Enterprise Value of 2426555136. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.52 while its Price-to-Book (P/B) ratio in mrq is 18.02. Its current Enterprise Value per Revenue stands at 9.21 whereas that against EBITDA is -30.305.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.93, which has changed by 1.3979359 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $21.72, while it has fallen to a 52-week low of $8.03. The 50-Day Moving Average of the stock is 19.60%, while the 200-Day Moving Average is calculated to be 39.45%.
Shares Statistics:
The stock has traded on average 1.78M shares per day over the past 3-months and 1936890 shares per day over the last 10 days, according to various share statistics. A total of 119.80M shares are outstanding, with a floating share count of 104.79M. Insiders hold about 12.61% of the company’s shares, while institutions hold 101.47% stake in the company. Shares short for ARQT as of 1759190400 were 14452315 with a Short Ratio of 8.14, compared to 1756425600 on 17018275. Therefore, it implies a Short% of Shares Outstanding of 14452315 and a Short% of Float of 14.89.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of Arcutis Biotherapeutics Inc (ARQT) in the stock market.The consensus estimate for the next quarter is -$0.03, with high estimates of $0.03 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.35 and -$0.49 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is $0.15, with 5.0 analysts recommending between $0.4 and -$0.21.
Revenue Estimates
7 analysts predict $87.41M in revenue for. The current quarter. It ranges from a high estimate of $92M to a low estimate of $83.5M. As of. The current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $44.76MFor the next quarter, 7 analysts are estimating revenue of $98.45M. There is a high estimate of $107.7M for the next quarter, whereas the lowest estimate is $92.28M.
A total of 8 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $347M, while the lowest revenue estimate was $323.13M, resulting in an average revenue estimate of $334.07M. In the same quarter a year ago, actual revenue was $196.54MBased on 8 analysts’ estimates, the company’s revenue will be $438.84M in the next fiscal year. The high estimate is $468.4M and the low estimate is $418.84M.
